Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
This multi-receptor approach distinguishes it from existing licensed medicines such as semaglutide (Ozempic, Wegovy) or tirzepatide licensed in the UK as Mounjaro for type 2 diabetes and as Zepbound for obesity which act on fewer receptor pathways
Do not freeze the medication
Retatrutide is an investigational peptide drug currently under clinical development by Eli Lilly
Optum Perks is owned by RVO Health
e P.IVA 01917390989 | REA BS 0381256 Crafted by 91%
US$ 29.24
US$ 21.46
US$ 29.43
US$ 28.97
